RPbio알피바이오
314140 · KOSDAQ · ₩314140 · 알피바이오
- Market cap
- ₩46B
- Enterprise value
- ₩47B
- P/E
- 6.8×
- P/B
- 0.4×
- Dividend yield
- 0.9%
- ROE
- 5.8%
- Net margin
- 4.8%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−38.3% from the high
₩4,810Today: ₩5,250 – ₩5,500₩8,590
Returns
- 1W−2.8%
- 1M−10.9%
- 3M−4.0%
- 6M−14.7%
- YTD−28.4%
- 1Y−29.8%
- Volume today
- 6,004
- 0.6× the 20-day average
- Traded today
- ₩32M
- Listed shares
- 8,666,361
- EPS (12 months)
- ₩776
- Earnings yield 14.6%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 37 of 100 (50 is a normal day for this stock).
- MomentumWeak-11.7% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
RPbio stock overview
RPbio (알피바이오, KRX: 314140) is listed on KOSDAQ, in the Biotech & Pharma sector. Alpha Biotech operates in two segments: over-the-counter (OTC) pharmaceuticals and health functional foods, primarily manufacturing soft capsules under OEM and ODM arrangements for major pharmaceutical and health food companies, including Yuhan and Chong Kun Dang. Its shares closed at ₩5,300 on Oct 26, 2026, down 2.39% on the day, giving it a market value of ₩46B.
Key facts
- Market cap
- ₩46B
- Sector
- Biotech & Pharma
- Latest price change
- −2.39%
- As of
- Oct 26, 2026
- Main business
- Alpha Biotech operates in two segments: over-the-counter (OTC) pharmaceuticals and health functional foods, primarily manufacturing soft capsules under OEM and ODM arrangements for major pharmaceutical and health food companies, including Yuhan and Chong Kun Dang.
Quick answers about RPbio
- What does RPbio do?
- Alpha Biotech operates in two segments: over-the-counter (OTC) pharmaceuticals and health functional foods, primarily manufacturing soft capsules under OEM and ODM arrangements for major pharmaceutical and health food companies, including Yuhan and Chong Kun Dang. The company was established in 1983 as a joint venture with RP Scherer and produces its products at facilities in Hwaseong, Gyeonggi Province, and Mado. Its products include cold medicines, pain relievers, vitamins, minerals, and omega-3 and vitamin D supplements, and it sells them to customers rather than through direct distribution.
- What is the market cap of RPbio?
- The market capitalisation of RPbio was ₩46B at the close on Oct 26, 2026.
- When is the next earnings report from RPbio?
- Korean companies rarely announce results dates in advance. Based on when RPbio filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
Company profile
Alpha Biotech operates in two segments: over-the-counter (OTC) pharmaceuticals and health functional foods, primarily manufacturing soft capsules under OEM and ODM arrangements for major pharmaceutical and health food companies, including Yuhan and Chong Kun Dang. The company was established in 1983 as a joint venture with RP Scherer and produces its products at facilities in Hwaseong, Gyeonggi Province, and Mado. Its products include cold medicines, pain relievers, vitamins, minerals, and omega-3 and vitamin D supplements, and it sells them to customers rather than through direct distribution.
Written by AI from the company's latest annual report.
- Korean name
- 알피바이오
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 윤재훈
- Founded
- Aug 2016
- Listed
- Sep 2022
- Listed shares
- 8,666,361
- Fiscal year ends
- Month 12
- Website
- rpskorea.com
Similar companies
- Samsung Biologics207940 · ₩67T₩1,452,000−0.95%
- Celltrion068270 · ₩44T₩190,000−2.26%
- Alteogen196170 · ₩15T₩218,500−2.67%
- Yuhan000100 · ₩6T₩81,700−3.54%
- SK biopharmaceuticals326030 · ₩5.9T₩75,800−1.43%
- HLB028300 · ₩5.2T₩39,250−5.65%
- Hanmi Pharm128940 · ₩4.5T₩352,500−2.49%
- SAM Chun Dang Pharm000250 · ₩4.4T₩188,900−5.17%
Recent filings
See all- Half-year report (Jun 2026)Aug 14, 2026
- Change of CEOJun 30, 2026
- Quarterly report (Mar 2026)May 15, 2026
- Change of Department AffiliationApr 30, 2026
- Report on Appointment, Dismissal, or Mid-Term Resignation of Independent DirectorsApr 1, 2026
Titles in Korean until English translations are added.
Also known as: RPbio / 알피바이오 / 314140 / KRX:314140
Source: KRX statistical information